Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Acumen Pharmaceuticals, Inc. (ABOS)

4.21   -0.08 (-1.86%) 09-27 16:00
Open: 4.29 Pre. Close: 4.29
High: 4.34 Low: 4.19
Volume: 190,655 Market Cap: 244(M)

Technical analysis

as of: 2023-09-27 4:17:26 PM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 6.59     One year: 7.7
Support: Support1: 4.11    Support2: 3.41
Resistance: Resistance1: 5.64    Resistance2: 6.59
Pivot: 5.06
Moving Average: MA(5): 4.38     MA(20): 5.32
MA(100): 5.89     MA(250): 5.78
MACD: MACD(12,26): -0.6     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 7     %D(3): 5.3
RSI: RSI(14): 19.6
52-week: High: 11.31  Low: 3.51
Average Vol(K): 3-Month: 1,195 (K)  10-Days: 322 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ABOS ] has closed above bottom band by 10.0%. Bollinger Bands are 1.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.42 - 4.45 4.45 - 4.47
Low: 4.15 - 4.19 4.19 - 4.22
Close: 4.23 - 4.29 4.29 - 4.34

Company Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Headline News

Tue, 19 Sep 2023
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat

Mon, 18 Sep 2023
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This ... - Nasdaq

Sun, 17 Sep 2023
Acumen Pharmaceuticals, Inc.'s (NASDAQ:ABOS) largest shareholders are private equity firms with 38% ownership, individual investors own 26% - Yahoo Finance

Wed, 06 Sep 2023
Acumen Pharmaceuticals to Participate in the H.C. - GlobeNewswire

Tue, 08 Aug 2023
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights - Yahoo Finance

Fri, 28 Jul 2023
Does Acumen Pharmaceuticals Inc (ABOS) Have What it Takes to be in Your Portfolio Friday? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 58 (M)
Shares Float 27 (M)
% Held by Insiders 7.8 (%)
% Held by Institutions 51.7 (%)
Shares Short 1,750 (K)
Shares Short P.Month 1,550 (K)

Stock Financials

EPS -1.06
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.11
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -16.8
Return on Equity (ttm) -24.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.56
Sales Per Share 0
EBITDA (p.s.) -0.91
Qtrly Earnings Growth 0
Operating Cash Flow -42 (M)
Levered Free Cash Flow -28 (M)

Stock Valuations

PE Ratio -3.98
PEG Ratio -0.5
Price to Book value 1.02
Price to Sales 0
Price to Cash Flow -5.77

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.